Table 5.
Comparison of indicators in the use of rhTPO for treatment of grade III and IV thrombocytopenia [n, (%)].
| Indicators | Use of recombinant human thrombopoietin (rhTPO) | Z/χ2 value | P Value | |
|---|---|---|---|---|
| Grade III (n = 94) | Grade IV (n = 39) | |||
| Days of treatment | 6.00 (4.00, 8.00) | 6.00 (4.00, 11.00) | −0.761 | 0.447 |
| Time to increase platelets (days) | 5.50 (3.00, 8.00) | 6.00 (3.00, 11.00) | −1.023 | 0.306 |
| Delay of the next chemoradiotherapy cycle (days) | 3.00 (0, 9.25) | 3.00 (0, 8.00) | −0.094 | 0.925 |
| Prolonged hospitalization due to platelet decline (days) | 3.50 (0, 7.00) | 5.00 (0, 8.00) | −1.304 | 0.192 |
| Increased hospitalization costs due to platelet decline | 6503.00 (5040.00, 9474.00) | 7440.00 (5874.00, 14410.00) | −1.871 | 0.061 |
| Platelet transfusion | ||||
| No | 67 (71.3) | 16 (41.0) | 10.752 | 0.001 |
| Yes | 27 (28.7) | 23 (59.0) | ||